ketorolac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anti-inflammatory agents, ibufenac derivatives	1529	74103-06-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketorolac ketorolac tromethamine ketorolac trometamol trometamol ketorolac (+/-)-Ketorolac keromin	A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity. Molecular weight: 255.27 Formula: C15H13NO3 CLOGP: 1.62 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 59.30 ALOGS: -2.70 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketorolac
ketorolac tromethamine
ketorolac trometamol
trometamol ketorolac
(+/-)-Ketorolac
keromin

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Molecular weight: 255.27
Formula: C15H13NO3
CLOGP: 1.62
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 59.30
ALOGS: -2.70
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
30	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	58 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	9.79 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.35 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 30, 1989	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	450.07	12.60	479	16408	310208	63161927
Punctate keratitis	85.80	12.60	22	16865	599	63471536
Ulcerative keratitis	78.89	12.60	29	16858	2681	63469454
Corneal epithelium defect	76.76	12.60	18	16869	334	63471801
Skin papilloma	74.53	12.60	33	16854	4936	63467199
Spinal epidural haematoma	72.82	12.60	22	16865	1105	63471030
Tendon disorder	63.37	12.60	31	16856	5812	63466323
Concussion	55.18	12.60	33	16854	9211	63462924
Renal infarct	51.61	12.60	18	16869	1429	63470706
Torsade de pointes	50.97	12.60	36	16851	13315	63458820
Eye irritation	50.71	12.60	44	16843	21927	63450208
Anterior chamber cell	50.16	12.60	14	16873	530	63471605
Myocardial reperfusion injury	48.02	12.60	10	16877	104	63472031
Aspirin-exacerbated respiratory disease	47.39	12.60	15	16872	880	63471255
Corneal oedema	47.27	12.60	17	16870	1476	63470659
Eye pain	44.77	12.60	50	16837	33804	63438331
Retinal pigment epitheliopathy	44.71	12.60	11	16876	252	63471883
Tracheal deviation	44.52	12.60	10	16877	152	63471983
Migraine	43.17	12.60	89	16798	103257	63368878
Anaphylactic reaction	43.00	12.60	69	16818	66031	63406104
Phrenic nerve paralysis	42.62	12.60	10	16877	186	63471949
Purpura fulminans	41.24	12.60	8	16879	56	63472079
Systemic lupus erythematosus	38.60	12.60	5	16882	208913	63263222
Cardiac arrest	36.66	12.60	78	16809	92467	63379668
Uterine perforation	34.31	12.60	22	16865	6941	63465194
Respiratory tract infection viral	34.01	12.60	15	16872	2222	63469913
Meniscus injury	33.88	12.60	22	16865	7092	63465043
Corneal disorder	33.64	12.60	14	16873	1800	63470335
Emotional distress	33.02	12.60	42	16845	32507	63439628
Injury	32.86	12.60	65	16822	73182	63398953
Alopecia	30.46	12.60	27	16860	337509	63134626
Musculoskeletal disorder	29.92	12.60	32	16855	20612	63451523
Post-traumatic stress disorder	29.42	12.60	18	16869	5233	63466902
Microsporidia infection	29.02	12.60	8	16879	289	63471846
Hand deformity	29.01	12.60	4	16883	159453	63312682
Immune thrombocytopenia	28.19	12.60	23	16864	10533	63461602
Synovitis	27.15	12.60	8	16879	186910	63285225
Intraocular pressure increased	27.01	12.60	18	16869	6060	63466075
Ventricular fibrillation	25.85	12.60	23	16864	11844	63460291
Sacroiliitis	25.83	12.60	14	16873	3243	63468892
Keratitis	25.18	12.60	14	16873	3408	63468727
Fibrosis	25.11	12.60	15	16872	4177	63467958
Visual acuity reduced	25.10	12.60	30	16857	21796	63450339
Ocular hyperaemia	24.80	12.60	32	16855	25112	63447023
Foreign body sensation in eyes	24.66	12.60	12	16875	2222	63469913
Pericarditis	24.66	12.60	3	16884	131576	63340559
Brain injury	24.61	12.60	18	16869	7025	63465110
Asymptomatic bacteriuria	24.49	12.60	7	16880	289	63471846
Ankylosing spondylitis	24.22	12.60	21	16866	10453	63461682
Monocytosis	23.99	12.60	8	16879	554	63471581
Myelomalacia	23.67	12.60	5	16882	56	63472079
Renal ischaemia	23.06	12.60	8	16879	625	63471510
Vision blurred	23.05	12.60	65	16822	91859	63380276
Treatment failure	22.75	12.60	109	16778	198934	63273201
Ventricular tachycardia	22.22	12.60	27	16860	19952	63452183
Apallic syndrome	22.04	12.60	8	16879	713	63471422
Wound	21.93	12.60	8	16879	163255	63308880
Nasal disorder	21.85	12.60	12	16875	2852	63469283
Hepatic enzyme increased	21.01	12.60	14	16873	202314	63269821
Corneal thinning	20.60	12.60	5	16882	108	63472027
Lower respiratory tract infection	20.46	12.60	5	16882	132302	63339833
Swelling	20.38	12.60	26	16861	275352	63196783
Tuberculin test positive	19.58	12.60	12	16875	3499	63468636
Dystonia	19.28	12.60	21	16866	13798	63458337
Depression	19.22	12.60	103	16784	196389	63275746
Obstruction gastric	19.14	12.60	8	16879	1039	63471096
Eye inflammation	18.87	12.60	14	16873	5585	63466550
Sleep disorder	18.83	12.60	56	16831	81510	63390625
Anxiety	18.61	12.60	110	16777	217431	63254704
Corneal abrasion	18.60	12.60	8	16879	1116	63471019
Abdominal pain	18.23	12.60	137	16750	293319	63178816
Kounis syndrome	18.22	12.60	9	16878	1721	63470414
Condition aggravated	17.75	12.60	174	16713	402043	63070092
Hypoxic-ischaemic encephalopathy	17.39	12.60	12	16875	4275	63467860
Brain death	17.36	12.60	11	16876	3399	63468736
Corectopia	17.30	12.60	3	16884	10	63472125
Product use issue	17.18	12.60	20	16867	220500	63251635
Persistent corneal epithelial defect	16.87	12.60	3	16884	12	63472123
Renal tubular injury	16.70	12.60	6	16881	519	63471616
Photophobia	16.70	12.60	22	16865	17613	63454522
Stomatitis	16.69	12.60	8	16879	138717	63333418
Corneal perforation	16.45	12.60	6	16881	542	63471593
Renal papillary necrosis	16.18	12.60	5	16882	271	63471864
Nephrolithiasis	16.17	12.60	35	16852	41949	63430186
Small intestinal obstruction	16.03	12.60	22	16865	18315	63453820
Fascial infection	15.47	12.60	3	16884	21	63472114
Intervertebral discitis	15.41	12.60	10	16877	3218	63468917
Spinal cord compression	15.40	12.60	11	16876	4137	63467998
Atrophy	15.30	12.60	8	16879	1724	63470411
Exposure to SARS-CoV-2	15.22	12.60	8	16879	1743	63470392
Atrial fibrillation	15.18	12.60	6	16881	116630	63355505
Abdominal discomfort	15.10	12.60	40	16847	320845	63151290
Opisthotonus	14.93	12.60	5	16882	351	63471784
Cold urticaria	14.86	12.60	4	16883	132	63472003
Corneal opacity	14.68	12.60	6	16881	737	63471398
Corneal dystrophy	14.67	12.60	5	16882	370	63471765
Respiratory rate decreased	14.59	12.60	10	16877	3525	63468610
Paraplegia	14.56	12.60	9	16878	2663	63469472
Death	14.52	12.60	51	16836	374330	63097805
Colitis ischaemic	14.47	12.60	16	16871	10692	63461443
Laryngeal dyspnoea	13.75	12.60	4	16883	176	63471959
Urticaria	13.63	12.60	83	16804	165719	63306416
Pulmonary embolism	13.39	12.60	64	16823	116620	63355515
Dysentery	13.19	12.60	6	16881	955	63471180
Mobility decreased	13.10	12.60	8	16879	121151	63350984
Drug-disease interaction	13.00	12.60	5	16882	523	63471612
Completed suicide	12.70	12.60	12	16875	145661	63326474

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation	162.25	16.86	84	7841	20922	34928084
Nightmare	157.45	16.86	73	7852	14318	34934688
Respiratory depression	137.15	16.86	69	7856	16176	34932830
Nephrolithiasis	130.97	16.86	83	7842	30250	34918756
Victim of child abuse	129.09	16.86	32	7893	895	34948111
Drug dependence	126.89	16.86	75	7850	24142	34924864
Epidural lipomatosis	105.67	16.86	28	7897	1026	34947980
Product used for unknown indication	98.01	16.86	26	7899	957	34948049
Product prescribing error	97.10	16.86	62	7863	22865	34926141
Juvenile idiopathic arthritis	89.41	16.86	28	7897	1869	34947137
Drug hypersensitivity	85.34	16.86	98	7827	80431	34868575
Hyperhidrosis	73.34	16.86	88	7837	75604	34873402
Treatment failure	69.27	16.86	68	7857	46629	34902377
Drug ineffective	66.49	16.86	240	7685	456511	34492495
Asthma-chronic obstructive pulmonary disease overlap syndrome	60.66	16.86	19	7906	1268	34947738
Breath sounds abnormal	60.31	16.86	30	7895	6851	34942155
Bronchial hyperreactivity	55.37	16.86	19	7906	1690	34947316
Ulcerative keratitis	51.30	16.86	18	7907	1711	34947295
Child abuse	50.81	16.86	13	7912	414	34948592
Anaphylactic reaction	49.68	16.86	48	7877	32253	34916753
Cataract	48.17	16.86	43	7882	26143	34922863
Pulmonary function test abnormal	47.53	16.86	19	7906	2591	34946415
Mesangioproliferative glomerulonephritis	43.17	16.86	8	7917	51	34948955
Obesity	42.86	16.86	30	7895	12848	34936158
Nausea	40.53	16.86	168	7757	339740	34609266
Angioedema	37.03	16.86	44	7881	37330	34911676
Ischaemic cardiomyopathy	33.98	16.86	20	7905	6369	34942637
Heart sounds abnormal	33.19	16.86	11	7914	879	34948127
Periorbital swelling	32.53	16.86	10	7915	627	34948379
Burning feet syndrome	32.49	16.86	7	7918	103	34948903
Intentional product misuse	31.59	16.86	45	7880	45566	34903440
Product use in unapproved indication	27.37	16.86	73	7852	117426	34831580
Drug abuse	26.64	16.86	65	7860	99031	34849975
Cardiomyopathy	25.87	16.86	25	7900	16783	34932223
Corneal thinning	25.20	16.86	6	7919	141	34948865
Gastrointestinal motility disorder	24.83	16.86	12	7913	2572	34946434
Asthma	23.73	16.86	38	7887	42618	34906388
Toxicity to various agents	23.62	16.86	8	7917	200354	34748652
Strabismus	22.78	16.86	10	7915	1721	34947285
Obstructive airways disorder	21.90	16.86	22	7903	15472	34933534
Corneal oedema	21.74	16.86	9	7916	1342	34947664
Urticaria	21.29	16.86	45	7880	62332	34886674
Product use issue	20.88	16.86	45	7880	63171	34885835
Death	20.43	16.86	37	7888	398012	34550994
Non-infectious endophthalmitis	19.67	16.86	5	7920	155	34948851
Eye swelling	19.54	16.86	17	7908	9978	34939028
Aspirin-exacerbated respiratory disease	19.44	16.86	6	7919	381	34948625
Bronchitis	18.86	16.86	34	7891	41929	34907077
Eye pain	18.81	16.86	19	7906	13443	34935563
Nasal disorder	18.67	16.86	9	7916	1919	34947087
Urine analysis abnormal	18.35	16.86	9	7916	1992	34947014
Eye disorder	18.21	16.86	16	7909	9512	34939494
Neuromuscular block prolonged	17.92	16.86	6	7919	495	34948511
Carcinoid crisis	17.36	16.86	5	7920	250	34948756
Blood chromogranin A increased	16.88	16.86	5	7920	276	34948730

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	346.11	12.67	407	20397	298509	79425075
Respiratory depression	134.56	12.67	86	20718	27544	79696040
Victim of child abuse	123.72	12.67	32	20772	921	79722663
Nightmare	122.24	12.67	79	20725	25782	79697802
Nephrolithiasis	105.50	12.67	97	20707	53194	79670390
Punctate keratitis	98.92	12.67	27	20777	959	79722625
Epidural lipomatosis	97.51	12.67	28	20776	1200	79722384
Drug dependence	88.16	12.67	78	20726	40691	79682893
Sedation	82.98	12.67	84	20720	51811	79671773
Anaphylactic reaction	81.85	12.67	105	20699	83638	79639946
Product used for unknown indication	78.62	12.67	25	20779	1519	79722065
Corneal epithelium defect	78.28	12.67	21	20783	698	79722886
Ulcerative keratitis	77.63	12.67	31	20773	3658	79719926
Skin papilloma	69.79	12.67	33	20771	5853	79717731
Spinal epidural haematoma	68.05	12.67	22	20782	1410	79722174
Tendon disorder	66.43	12.67	34	20770	7152	79716432
Juvenile idiopathic arthritis	60.48	12.67	28	20776	4735	79718849
Anterior chamber cell	55.15	12.67	17	20787	932	79722652
Corneal oedema	55.07	12.67	22	20782	2598	79720986
Eye pain	54.97	12.67	58	20746	37520	79686064
Product prescribing error	49.88	12.67	60	20744	44753	79678831
Child abuse	48.93	12.67	13	20791	416	79723168
Bronchial hyperreactivity	48.61	12.67	21	20783	3019	79720565
Myocardial reperfusion injury	48.21	12.67	10	20794	104	79723480
Drug ineffective	47.37	12.67	459	20345	1080454	78643130
Aspirin-exacerbated respiratory disease	47.17	12.67	16	20788	1191	79722393
Asthma-chronic obstructive pulmonary disease overlap syndrome	44.24	12.67	20	20784	3201	79720383
Tracheal deviation	43.61	12.67	10	20794	171	79723413
Torsade de pointes	41.84	12.67	37	20767	19275	79704309
Renal infarct	41.10	12.67	18	20786	2673	79720911
Pulmonary function test abnormal	39.45	12.67	20	20784	4124	79719460
Hyperhidrosis	39.20	12.67	107	20697	151385	79572199
Foreign body sensation in eyes	38.13	12.67	16	20788	2141	79721443
Concussion	37.60	12.67	26	20778	9477	79714107
Phrenic nerve paralysis	37.31	12.67	10	20794	331	79723253
Angioedema	36.91	12.67	69	20735	75966	79647618
Uterine perforation	36.72	12.67	22	20782	6281	79717303
Mesangioproliferative glomerulonephritis	36.06	12.67	8	20796	117	79723467
Breath sounds abnormal	35.38	12.67	31	20773	15953	79707631
Injury	33.55	12.67	67	20737	77429	79646155
Ischaemic cardiomyopathy	32.69	12.67	22	20782	7673	79715911
Nasal disorder	32.44	12.67	17	20787	3752	79719832
Eye irritation	32.18	12.67	33	20771	20648	79702936
Immune thrombocytopenia	30.62	12.67	30	20774	17775	79705809
Migraine	30.21	12.67	69	20735	87424	79636160
Ocular hyperaemia	30.14	12.67	37	20767	28169	79695415
Vision blurred	29.61	12.67	77	20727	105821	79617763
Visual acuity reduced	28.85	12.67	37	20767	29432	79694152
Urticaria	28.09	12.67	109	20695	185092	79538492
Corneal thinning	27.59	12.67	7	20797	186	79723398
Purpura fulminans	27.28	12.67	7	20797	195	79723389
Burning feet syndrome	27.21	12.67	7	20797	197	79723387
Intraocular pressure increased	26.95	12.67	21	20783	9184	79714400
Heart sounds abnormal	26.58	12.67	11	20793	1422	79722162
Corneal opacity	26.53	12.67	10	20794	1010	79722574
Strabismus	26.45	12.67	13	20791	2508	79721076
Musculoskeletal disorder	25.99	12.67	30	20774	21418	79702166
Renal tubular injury	25.96	12.67	11	20793	1508	79722076
Death	25.63	12.67	70	20734	566444	79157140
Respiratory tract infection viral	25.16	12.67	15	20789	4244	79719340
Keratitis	24.95	12.67	15	20789	4307	79719277
Emotional distress	24.23	12.67	40	20764	39929	79683655
Post-traumatic stress disorder	23.27	12.67	15	20789	4866	79718718
Meniscus injury	23.27	12.67	17	20787	6751	79716833
Sleep disorder	22.63	12.67	61	20743	85616	79637968
Eye disorder	22.30	12.67	29	20775	23383	79700201
Synovitis	22.07	12.67	6	20798	150728	79572856
Drug abuse	21.68	12.67	92	20712	162599	79560985
Corneal disorder	21.64	12.67	11	20793	2280	79721304
Corneal abrasion	21.26	12.67	9	20795	1230	79722354
Lower respiratory tract infection	21.21	12.67	4	20800	129216	79594368
Cardiac arrest	20.41	12.67	94	20710	172002	79551582
Microsporidia infection	19.92	12.67	8	20796	958	79722626
Apallic syndrome	19.90	12.67	8	20796	960	79722624
Eye inflammation	19.58	12.67	15	20789	6398	79717186
Monocytosis	19.46	12.67	8	20796	1016	79722568
Myelomalacia	19.39	12.67	5	20799	142	79723442
Nausea	19.16	12.67	353	20451	956843	78766741
Renal ischaemia	18.49	12.67	8	20796	1154	79722430
Obstruction gastric	18.19	12.67	9	20795	1761	79721823
Abdominal pain	18.18	12.67	168	20636	389401	79334183
Cardiac failure	17.91	12.67	9	20795	154833	79568751
Cardiomyopathy	17.71	12.67	29	20775	28745	79694839
Tuberculin test positive	17.56	12.67	11	20793	3397	79720187
Fibrosis	17.50	12.67	13	20791	5296	79718288
Systemic lupus erythematosus	17.40	12.67	5	20799	121144	79602440
Corectopia	17.36	12.67	3	20801	10	79723574
Brain injury	17.23	12.67	18	20786	11499	79712085
Febrile neutropenia	17.16	12.67	21	20783	230978	79492606
Eye swelling	16.73	12.67	27	20777	26441	79697143
Hepatic enzyme increased	16.52	12.67	14	20790	182596	79540988
Ankylosing spondylitis	16.37	12.67	18	20786	12187	79711397
Neuromuscular block prolonged	16.09	12.67	7	20797	1023	79722561
Photophobia	15.88	12.67	23	20781	20505	79703079
Pericarditis	15.54	12.67	4	20800	104232	79619352
Cold urticaria	15.53	12.67	4	20800	113	79723471
Non-infectious endophthalmitis	15.38	12.67	5	20799	326	79723258
Cataract	15.18	12.67	43	20761	62077	79661507
Back pain	15.11	12.67	133	20671	304047	79419537
Flank pain	15.01	12.67	22	20782	19822	79703762
Toxicity to various agents	14.93	12.67	58	20746	421482	79302102
Stomatitis	14.88	12.67	10	20794	146747	79576837
Sickle cell anaemia with crisis	14.85	12.67	14	20790	7908	79715676
Asymptomatic bacteriuria	14.83	12.67	5	20799	365	79723219
General physical health deterioration	14.81	12.67	31	20773	275207	79448377
Obesity	14.75	12.67	30	20774	35095	79688489
Heparin-induced thrombocytopenia test positive	14.74	12.67	4	20800	139	79723445
Eyelid oedema	14.69	12.67	18	20786	13669	79709915
Completed suicide	14.68	12.67	26	20778	245741	79477843
Corneal perforation	14.64	12.67	6	20798	757	79722827
Iris atrophy	14.24	12.67	4	20800	158	79723426
Exposure to SARS-CoV-2	14.20	12.67	8	20796	2036	79721548
Renal papillary necrosis	14.10	12.67	5	20799	425	79723159
Periorbital swelling	14.06	12.67	9	20795	2887	79720697
Interstitial lung disease	13.86	12.67	6	20798	112594	79610990
Gastrointestinal motility disorder	13.80	12.67	12	20792	6110	79717474
Decreased appetite	13.52	12.67	45	20759	342373	79381211
Lip oedema	13.48	12.67	12	20792	6304	79717280
Diarrhoea	13.47	12.67	156	20648	880333	78843251
Alopecia	13.35	12.67	25	20779	231330	79492254
Blood chromogranin A increased	13.34	12.67	5	20799	497	79723087
Ventricular tachycardia	13.30	12.67	32	20772	41903	79681681
Treatment failure	13.19	12.67	15	20789	170471	79553113
Carcinoid crisis	13.14	12.67	5	20799	518	79723066
Hypoxic-ischaemic encephalopathy	13.12	12.67	13	20791	7807	79715777
Wound	13.06	12.67	7	20797	116172	79607412
Embedded device	12.94	12.67	9	20795	3310	79720274
Mobility decreased	12.83	12.67	8	20796	122167	79601417
Persistent corneal epithelial defect	12.69	12.67	3	20801	59	79723525
Hepatic neoplasm	12.68	12.67	9	20795	3417	79720167

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AB15	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances
ATC	S01BC05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
ATC	S01FB51	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Sympathomimetics excl. antiglaucoma preparations
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50629	COX-2 inhibitor
CHEBI has role	CHEBI:50630	COX-1 inhibitor
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug
FDA EPC	N0000175939	Cyclooxygenase Inhibitor
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Severe pain	indication	76948002
Allergic conjunctivitis	indication	473460002	DOID:11204
Acute postoperative pain	indication	107401000119105
Postoperative Ocular Pain	indication
Post-Op Ocular Inflammation	indication
Post-Op Photophobia	indication
Renal colic	off-label use	7093002
Peptic ulcer	contraindication	13200003	DOID:750
Disorder of cornea	contraindication	15250008	DOID:10124
Acute gastric ulcer with perforation	contraindication	19850005
Myocardial infarction	contraindication	22298006	DOID:5844
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Tear film insufficiency	contraindication	46152009
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Corneal erosion	contraindication	50792001
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Rheumatoid arthritis	contraindication	69896004	DOID:7148
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Hemophilia	contraindication	90935002
Corneal degeneration	contraindication	111521006	DOID:1237
Perioperative care	contraindication	133897009
Asthma	contraindication	195967001	DOID:2841
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Cerebral hemorrhage	contraindication	274100004
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Smokes tobacco daily	contraindication	449868002
Preoperative Pain Management	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.47	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.3% BASE;EQ 1% BASE	OMIDRIA	RAYNER SURGICAL	N205388	May 30, 2014	RX	SOLUTION	IRRIGATION	8173707	July 30, 2023	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
EQ 0.3% BASE;EQ 1% BASE	OMIDRIA	RAYNER SURGICAL	N205388	May 30, 2014	RX	SOLUTION	IRRIGATION	9278101	July 30, 2023	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8207215	May 28, 2024	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8377982	May 28, 2024	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8541463	May 28, 2024	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8906950	May 28, 2024	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8946281	May 28, 2024	A METHOD OF TREATING OCULAR PAIN
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	9216167	May 28, 2024	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
0.4%	ACULAR LS	ABBVIE	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8008338	May 24, 2027	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	6.90	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	9.72	WOMBAT-PK	CHEMBL
Serine/threonine-protein kinase PAK 1	Kinase	Q13153	PAK1_HUMAN		IC50	4.44	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	4.94	CHEMBL
Aldose reductase	Enzyme		ALDR_RAT		IC50	5.21	DRUG MATRIX
Prostaglandin-H2 D-isomerase	Enzyme		PTGDS_MOUSE		IC50	6.64	CHEMBL

External reference:

ID	Source
4028637	VUID
N0000178380	NUI
D00813	KEGG_DRUG
74103-07-4	SECONDARY_CAS_RN
4019510	VANDF
4028637	VANDF
C0073631	UMLSCUI
CHEBI:6129	CHEBI
KTR	PDB_CHEM_ID
CHEMBL469	ChEMBL_ID
CHEMBL1201124	ChEMBL_ID
DB00465	DRUGBANK_ID
D020910	MESH_DESCRIPTOR_UI
3826	PUBCHEM_CID
6661	IUPHAR_LIGAND_ID
5558	INN_ID
YZI5105V0L	UNII
28200	RXNORM
30341	MMSL
39892	MMSL
4947	MMSL
9780	MMSL
d00273	MMSL
003539	NDDF
004812	NDDF
108512006	SNOMEDCT_US
108513001	SNOMEDCT_US
372501008	SNOMEDCT_US
D020911	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acular	HUMAN PRESCRIPTION DRUG LABEL	1	0023-2181	SOLUTION/ DROPS	5 mg	OPHTHALMIC	NDA	23 sections
Acular	HUMAN PRESCRIPTION DRUG LABEL	1	0023-2181	SOLUTION/ DROPS	5 mg	OPHTHALMIC	NDA	23 sections
ACUVAIL	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3507	SOLUTION/ DROPS	4.50 mg	OPHTHALMIC	NDA	23 sections
ACUVAIL	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3507	SOLUTION/ DROPS	4.50 mg	OPHTHALMIC	NDA	23 sections
ACUVAIL	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3507	SOLUTION/ DROPS	4.50 mg	OPHTHALMIC	NDA	23 sections
ACULAR LS	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9277	SOLUTION/ DROPS	4 mg	OPHTHALMIC	NDA	22 sections
ACULAR LS	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9277	SOLUTION/ DROPS	4 mg	OPHTHALMIC	NDA	22 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0314	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0314	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0314	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0069	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0069	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0072	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0072	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0076	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0076	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1134	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9883	INJECTION, SOLUTION	30 mg	INTRAVENOUS	ANDA	15 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9883	INJECTION, SOLUTION	30 mg	INTRAVENOUS	ANDA	15 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9883	INJECTION, SOLUTION	30 mg	INTRAVENOUS	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9884	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9884	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	15 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9952	INJECTION, SOLUTION	15 mg	INTRAVENOUS	ANDA	15 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9952	INJECTION, SOLUTION	15 mg	INTRAVENOUS	ANDA	15 sections
Ketorolac tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9996	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	13 sections
Ketorolac tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9997	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	13 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3793	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3793	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3793	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3795	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	15 sections